MIM
GLUE icon

MetLife Investment Management’s Monte Rosa Therapeutics GLUE Stock Holding History

MetLife Investment Management’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$550K Buy
33,409
+7,222
+28% +$138K ﹤0.01% 1705
2025
Q4 		$411K Buy
26,187
+1,831
+8% +$24.7K ﹤0.01% 1883
2025
Q3 		$180K Hold
24,356
– – ﹤0.01% 2377
2025
Q2 		$110K Hold
24,356
– – ﹤0.01% 2493
2025
Q1 		$113K Sell
24,356
-499
-2% -$3.06K ﹤0.01% 2472
2024
Q4 		$172K Hold
24,855
– – ﹤0.01% 2371
2024
Q3 		$132K Buy
+24,855
New +$125K ﹤0.01% 2509
2024
Q2 		– Sell
-11,419
Closed -$80.5K – 2899
2024
Q1 		$80.5K Sell
11,419
-6,738
-37% -$40K ﹤0.01% 2628
2023
Q4 		$103K Hold
18,157
– – ﹤0.01% 2597
2023
Q3 		$87K Hold
18,157
– – ﹤0.01% 2647
2023
Q2 		$124K Hold
18,157
– – ﹤0.01% 2553
2023
Q1 		$141K Hold
18,157
– – ﹤0.01% 2404
2022
Q4 		$138K Hold
18,157
– – ﹤0.01% 2451
2022
Q3 		$148K Hold
18,157
– – ﹤0.01% 2469
2022
Q2 		$176K Hold
18,157
– – ﹤0.01% 2408
2022
Q1 		$255K Buy
+18,157
New +$252K ﹤0.01% 2205
2021
Q4 		– Sell
-4,756
Closed -$106K – 2521
2021
Q3 		$106K Buy
+4,756
New +$136K ﹤0.01% 2423

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

MetLife Investment Management's GLUE Position: Q1 2026 in Review

MetLife Investment Management increased its Monte Rosa Therapeutics (GLUE) stake by 28% in Q1 2026, buying an estimated $138K and bringing the position to 33,409 shares worth $550K. The position accounts for ﹤0.01% of the portfolio, ranked #1705.

MetLife Investment Management first reported a position in GLUE in Q3 2021 and has held it in 17 quarters since. 190 funds tracked by Wall St. Rank hold GLUE as of Q1 2026.

  • MetLife Investment Management held 33,409 shares of Monte Rosa Therapeutics worth $550K as of Q1 2026.
  • MetLife Investment Management bought 7,222 Monte Rosa Therapeutics shares in Q1 2026, an estimated $138K.
  • Monte Rosa Therapeutics made up ﹤0.01% of MetLife Investment Management's portfolio in Q1 2026, its #1705 holding.
  • MetLife Investment Management first reported a position in Monte Rosa Therapeutics in Q3 2021 and has held it in 17 quarters since.
  • 190 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.